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Abstract
The article reviews the use of robotic technology for head and neck tumours. The authors discuss the development of transoral robotic 
surgery (TORS), the current status of the technology, and the set-up in the operating room. The article provides a review of the literature, 
highlighting the applications, advantages, functional outcomes, and disadvantages of TORS for each anatomic subsite (oropharynx, 
hypopharynx, larynx, parapharyngeal space, and skull base). New challenges related to reconstruction are also presented. Overall early 
functional and oncologic outcome data are promising; further long-term prospective trials are still needed to confirm the oncological safety 
of TORS.
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Introduction
Robotic-assisted surgery has its roots in 1972, when the National Aeronautics and Space Administration began to investigate a method to 
provide surgical care to orbiting astronauts through telepresence surgery [1].
After the first laparoscopic splenectomy performed in 1997 [2], robotic-assisted surgery has gained popularity in several surgical specialties 
such as general, urological, cardiothoracic, gynecological, orthopedic, and neurological surgeries [3].
Transoral robotic surgery (TORS) was first introduced in [4] by Weinstein et al with a case report of a supraglottic laryngectomy in a canine 
model and by MacLeod and Melder [5], who reported the excision of a vallecular cyst in a human patient with a setup time of 75 min and 
a surgical time of 30 min. Since these early reports, the development of TORS has been steadily progressing and many other studies on 
TORS in animal cadavers, human subjects, and various head and neck cancer sites have been published. 
In 2006 and 2007, preclinical and clinical studies by a team at the University of Pennsylvania demonstrated [6–8] the feasibility and safety of 
transoral resections with the assistance of the Da Vinci Surgical Robot (Intuitive Surgical Inc., Sunnyvale, California, United States), such that 
the US Food and Drug Administration approved TORS for selected benign and malignant head and neck tumours in December 2009 [9].
Because of the possibility of obtaining superior visualisation and complete resection of tumours with wide margins, TORS seems to 
represent an alternative to open or endoscopic/microscopic approaches in oral and pharyngolaryngeal oncology—particularly with 5-mm 
instruments—that allows improved vision, greater ease of use, and a shorter operating time [10].
Current robotic system
The Da Vinci Surgical System consists of three components: a surgeon’s console, a patient-side robotic cart equipped with four arms, and 
a high-definition three-dimensional vision cart. Articulating surgical instruments are mounted on the robotic arms, which are introduced into 
the upper aerodigestive tract through the mouth of the patient and manipulated remotely with master robot manipulators from the surgeon’s 
console. 
As far as head and neck surgery is concerned, usually only three of the four arms are employed: one to handle a 12-mm stereoscopic 
endoscope at an angle of 0° or 30° and the other two equipped with 5-mm endo wrist instruments (Intuitive Surgical Inc.). 
Both the endoscope and the robotic instruments are introduced transorally and allow the surgeon to perform procedures equivalent to 
traditional surgery, with the advantages of enhanced three-dimensional HD visualisation, wide range of motion with seven degrees of 
freedom, reduction of hand tremors, possibility of navigating around corners through angled scopes, reduction of fatigue, proper hand–
eye coordination, and the possibility of telesurgery and teaching opportunities with more favourable learning curves [3, 11–14].
When compared with open surgical approaches, TORS may avoid disfiguring mandibulotomy; it reduces the need for adjuvant radio and/or 
chemotherapy and for tracheostomy/gastrostomy, improves the return to normal speech and swallowing, and reduces blood loss and 
postoperative pain [7, 15–17]. Minimal scarring with reduced risk of wound infection, shorter hospital stays, and shorter recovery times may 
also improve patients’ quality of life (QOL) [18].
TORS may be applied for benign and malignant lesions of the palate, the palatine tonsils, the base of the tongue, the posterior and lateral 
pharyngeal wall, the parapharyngeal space, the larynx, and the hypopharynx; main contraindications are reduced mouth opening, incom-
plete lesion visualisation, mandible involvement, tumours involving >50% of the base of the tongue or of the posterior pharyngeal wall, 
internal carotid artery, or prevertebral fascia involvement [7].
Surgical setup 
TORS is defined as the surgery performed through the oral cavity that uses a minimum of three robotic arms and allows bimanual manipulation 
of tissues. The surgeon’s cart should be located at the end of the operating room, allowing free space to manoeuver the surgical cart that is 
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placed on the left side of the patient, opposite to the surgeon [19]. The assistant is seated at the head of the patient. The anaesthesia machine 
and anaesthesiologist are at the patient’s foot. After induction, the endoscopic tower and scrub table are placed on the right; the patient should 
be placed in a strictly supine position on the operating table [14]. The surgeon places a Crow–Davis mouth gag (suspended to the bed) to 
gain surgical exposure and three sterilely draped robotic arms are placed in surgical position: the instruments (atraumatic forceps and elec-
trocautery spatula tip) are introduced 30° laterally from the arm supporting the 0° endoscope and placed in the right and left arms of the robot. 
In laryngeal and pharyngeal surgeries, a Feyh–Kastenbauer (FK) retractor can be used and a flexible aspiration tube for smoke aspiration is 
introduced into the nasopharynx through one of the nostrils.
All of the authors stress the importance of the correct positioning of the machine, to allow complete exposition of the lesion and free, 
unobstructed movements of the robotic arms [3, 11–14].
Oropharynx
Tongue base
In 2006, O’Malley et al reported a prospective clinical trial evaluating the use of TORS in three patients with tongue base cancer. They 
reported an excellent visualisation and tumuor removal possibility. The use of the FK retractor is described to be essential for proper 
exposure and for instrument manoeuverability. Complete resection with negative surgical margins was achieved in all three cases with an 
excellent control of bleeding; no intraoperative or postoperative complications were encountered [15].
The use of Da Vinci robot has also been reported for tongue base biopsy in the evaluation of unknown primary tumours of the head and neck 
[20]. Metha et al reported a retrospective study on ten patients with unknown primary tumours of the head and neck. All patients underwent a 
cervical biopsy, positron-emission tomography/computed tomography, formal endoscopy, bilateral tonsillectomy, and transoral robotic base 
of tongue resection. Robot-assisted base of tongue resection identified primary tumours in 90% patients with minimal morbidity [21].
Reconstruction should be considered particularly for large defects, to maintain a balance between restoration of bulk and maintaining 
a sensate mucosal surface, so as not to impair the pharyngeal phase of swallowing and to avoid aspiration [22]. The radial forearm 
flap is the most frequently used [23]. For smaller defects, secondary healing and remucosalisation seem to provide adequate function 
preservation. 
Tonsillar region
TORS radical tonsillectomy has widened the indications for transoral resection, because TORS allows excellent visualisation in all directions, 
concurrent tongue base resection, and the possibility of better identifying small and large vessels. In the series of 27 patients presented by 
Weinstein et al, TORS seems to represent a valid alternative to transmandibular approaches with free-flap reconstruction. All the patients 
underwent TORS radical tonsillectomy for invasive squamous cell carcinoma (SCC) of the tonsillar region, staged neck dissection, and adju-
vant therapy. Major tumour-related contraindications for TORS radical tonsillectomy were: unresectability of involved neck nodes, mandibular 
invasion, tongue base invasion requiring a resection of >50% of the tongue base, pharyngeal wall involvement necessitating resection of 
>50% of the posterior pharyngeal wall, radiological confirmation of carotid artery involvement, and fixation of tumour to prevertebral fascia. 
Neck dissection was performed one to three weeks following TORS radical tonsillectomy, to avoid the risk of creating a connection between 
the pharynx and the neck and to avoid additional laryngopharyngeal swelling that might require a tracheotomy. No free-flap reconstruction 
was needed and the mucosal defect at the end of surgery was allowed to heal by secondary intention. The mean operative time to perform 
TORS was 1 h and 43 min including a mean of 9 min for exposure and robotic positioning. Complete resection with negative surgical margins 
was achieved in 93% of the cases. The surgical complication rate was 19%, most cases resolving without significant sequelae: one mucosal 
haemorrhage requiring a return to the operating room, one tracheostomy for OSA exacerbation, two cases of trismus, and one of hyperna-
sality requiring an outpatient procedure for correction. No mortality occurred and no cases of pneumonia or fistula were observed. Twenty 
patients were extubated at the end of the surgical procedure, the remaining six patients remained intubated for laryngopharyngeal swelling, 
treated with steroids for one to three days and then extubated after an average of 2.7 days postoperatively. One patient required unplanned 
tracheostomy for his sleep aponea exacerbation. All the patients underwent percutaneous gastrostomy and 96% of them recovered a proper 
swallowing function at the follow-up [7]. 
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For the majority of the patients, no reconstruction is required if the resection is limited to the tonsillar region; free tissue transfer should be 
considered in patients predisposed to poor wound healing, or if the carotid artery is exposed in the parapharyngeal space [22]. When the 
resection involves soft palate tissue, restoring competence of the velopharyngeal sphincter is mandatory; palatal defects involving less than 
one-quarter can be reconstructed with primary closure or simple approximation to the flap, while more extended defects require soft tissue 
free flaps, mainly radial forearm, and pharyngeal flaps [24].
Larynx
Weinstein et al reported a prospective human clinical trial evaluating the use of TORS in three cases of supraglottic partial laryngectomy 
for supraglottic carcinoma. An excellent surgical exposure with complete tumour resection was achieved. No intraoperative or postopera-
tive complications were reported. The median overall operation time was 120 min including 18 min for exposure and robotic positioning. 
Robotic-assisted supraglottic laryngectomy is reported to be technically feasible and relatively safe, representing an alternative to open 
approaches and conventional transoral supraglottic partial laryngectomy [8].
Solares and Strome reported three cases of CO2 laser robotic-assisted supraglottic laryngectomy. The FK laryngo-pharyngoscope was 
reported to provide excellent visualisation in only one patient, and the procedure was completed successfully. In the other two cases, 
adequate exposure could not be achieved and more traditional techniques were performed [25].
Park et al [26] reported a prospective human trial with four patients with glottic carcinoma successfully treated with TORS; no perioperative 
complications were reported and all surgical margins were disease free.
Hypopharynx
Although hypopharyngeal SCC represents a clinically distinct and less frequent entity among other cancers of the head and neck, early 
experiences using TORS for hypopharyngectomy for I- and II-staged cancers seem to be promising. 
Park et al reported a series of ten patients with T1 or T2 pyriform sinus and posterior pharyngeal wall cancer successfully treated with 
TORS. The mean operation time was 62.4 min with an average of 17.5 min for the robot setup. No significant perioperative complications 
were reported. A return to normal swallowing function was observed in all patients within 8.3 days average and decannulation within 
6.3 days after surgery. The authors concluded that transoral robotic hypopharyngectomy is feasible and safe for the treatment of early 
hypopharyngeal tumours [27].
Parapharyngeal space and infratemporal fossa
TORS used in skull base surgery was first assessed in [28] on animal and cadaver models. They also reported one case of benign neoplasm 
of the parapharyngeal space and infratemporal fossa treated with TORS. Robotic approach allowed an excellent access, visualisation, and 
tissue dissection within the parapharyngeal space and infratemporal fossa, providing a safe identification of the internal carotid artery and 
cranial nerves, and excellent haemostasis. However, certain limitations were observed in the TORS approach, notably its inability to perform 
wide resection, which may be required for invasive malignant neoplasm. Therefore, the authors concluded that TORS may be best suited for 
excising well-circumscribed benign lesions, adenomas or schwannomas, and possibly limited parapharyngeal metastatic lymph nodes.
In 2010, the same authors assessed the outcomes of ten patients undergoing parapharyngeal space resection using the TORS 
approach [29]. The surgery was performed in 90% of the cases without significant complications, with acceptable operative time and 
blood loss; one case was converted to an open transcervical approach due to difficulties found during TORS resection. In 70% of the 
cases, it was a pleomorphic adenoma and in those patients the reported local control rate was 100%. A decrease of complication rate 
was noted in TORS when compared with traditional transcervical surgery.
McCool et al [30] reported six complete and two partial dissections of the infratemporal fossa carried out in cadaver models using a 
suprahyoid port, whereas the second arm and 30° camera were placed transorally.
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In cadaveric dissections, Hanna et al [31] obtained excellent access to the anterior and central skull base, including the cribriform plate, fovea eth-
moidalis, medial orbits, planum sphenoidale, sella turcica, suprasellar and parasellar regions, nasopharynx, pterygopalatine fossa, and clivus. 
In skull base surgery, robotic techniques can be considered as the natural evolution of traditional endoscopic techniques [32] and their 
role is evolving with the goal of maximising surgical resections without compromising oncological principles. Kupferman et al [33] reported 
using robotic technology to greatly facilitate the suture-based dural reconstruction of the anterior cranial base in a cadaver model, ensuring 
a minimal trauma to surrounding critical neurovascular structures. 
Head and neck robotic reconstructive surgery
As the application of TORS for the treatment of head and neck cancer increases, robotically assisted reconstruction, whether using free 
flaps, local flaps, or primary closure, holds the potential of expanding TORS applications, keeping the aim to provide patients with less 
morbid procedures. The introduction of vascularised tissue into an oropharyngeal defect can provide improved functional recovery. The 
flexibility of the robotic arms allows suture placement transorally in areas of decreased visibility using traditional open techniques. Even 
microvascular anastomosis has proved faster and more effective [34]. In robotic-assisted microvascular anastomosis, the robotic arms are 
placed almost horizontally, in the plane of the bed, and in direct proximity of the external incision; a third arm serves as a stationary assis-
tant, while Black Diamond Micro Needle drivers (Intuitive Surgical) and 9.0 nylon suture are used for the anastomosis [35].
Several case series demonstrated the clinically applicable use of the robot for reconstruction of head and neck.
Mukhija et al [36] described the first two cases of TORS-assisted free flap (radial forearm) reconstruction of orophayrnx and oral cavity: for 
both cases, the flaps were inset robotically, while the microanastomosis was performed in the standard fashion. 
Selber reported robotic-assisted reconstruction in five patients with oropharyngeal tumours: reconstruction included both local and free 
flaps, depending on the size of the defect, prior radiation, and the presence or absence of a pharyngotomy. The authors reported the first 
case of robotic anastomosis, with the advantage of tremor elimination, motion scaling up to 5:1, and an enhanced ability to work precisely 
in confined spaces. There were no oropharyngeal fistulas. Only one postoperative complication was reported; one patient accidentally bit 
through his pedicle but without resulting flap failure [35]. Genden et al [37] reported a series of 31 patients who underwent TORS recon-
struction: promising results are presented with 25 cases of reconstruction with local advancement musculomucosal flap and six with a radial 
forearm free flap. The authors reported that patients who have been treated with radiation and patients with extensive defects needed 
free-flap reconstruction because the mucosa was often friable and poorly vascularised. Three patients required a transoral marginal mandi-
bulectomy. All the flaps were inserted robotically, but the anastomosis was done in the standard fashion. None of the patients developed a 
fistula. Ghanem presented a four-patient case series using robotic free-flap reconstruction. Tumour sites ranged from the tonsil to the base 
of the tongue and the oral tongue. Three patients received radial forearm free flaps, one a vastus lateralis free flap. All the flaps were inset 
robotically, with manual microvascular anastomosis. No fistulas were reported, but complications consisted of one neck infection and one 
partial dehiscence at the anterior tonsillar pillar (allowed to heal by secondary intention) [38]. 
Longfield et al performed 20 robot-assisted oropharyngeal reconstructions, including six anterolateral thigh flaps, five radial forearm flaps, 
two ulnar artery perforator flaps, two FAMM flaps, five buccal or pharyngeal transposition flaps. Robotic microvascular anastomosis was 
performed in four of these cases. No flap losses were described [34]. 
Song et al reported a case series of five patients who underwent robotic free-flap reconstruction (four radial forearm free flap and 
one anterolateral thigh free flap) after TORS for oropharynx tumours. In one case, the microanastomosis was performed using the 
robotic arms. No major complications were encountered, including flap failure, haematoma, or wound dehiscence [39].
Longfield et al provided an algorithmic approach to determine the need of reconstruction after robotic excision of head and neck tumours. 
TORS is not routinely necessary for tumours within the oral cavity, which usually offer a good manual transoral access. Retromolar trigone 
represents the only exception and, because of its anatomical features, tumours of this region may benefit from TORS resection and recon-
struction: in these cases, local flaps are usually sufficient for reconstruction. Tumours of the oropharynx (tonsil, base of the tongue, and soft 
palate) are an ideal indication for TORS resection: complicated excisions (involving carotid sheath exposure, bone exposure, and so on) 
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with resulting large defect may benefit from microvascular reconstruction. For supraglottic larynx, Longfield et al [34] considered that the 
reconstruction with free flap is often impractical, although in patients with a good oral aperture, it is technically feasible to resect robotically 
tumours in the supra- and infrahyoid regions.
Functional outcomes of TORS
Early TORS data support impressive functional outcomes with low rates of gastrostomy dependency, prompt decannulation, and resump-
tion of normal oral intake (Table 1).
Table 1. Functional outcomes of TORS.
Author Primary site Number of  
patients
Complications 
rate (%)
Tracheostomy 
(%)
Gastrostomy 
Tube (%)
 Palatine tonsil 27  
Base of tongue 11
Hurtuk et al, 2011 Larynx 4 0 0 17
[42] Retromolar trigone 1
Parapharynx 1
Total 44
 Tonsil 7    
Base of tongue 3
Genden et al, 2009 Parapharynx 2 0 0 0
[16] Hypopharynx 4
Palate 2
Total 18
Oropharynx 18    
Hans et al, 2011 Larynx 5 4,5 0 9
[49] Hypopharynx 2
Total 25
 Oropharynx 44    
Vergez et al, 2012 Hypopharynx 64 20,6 15 nd
[50] Larynx 18
Total 126
 Pharynx 2    
Remacle et al, 2012 Supraglottic 2 0 0 nd
[51] Total 4
Weinstein et al, 2007 [7] Oropharynx 27 14.8 3.7 4
Park et al, 2009 [52] Tonsil 5 0 100 0
 Tonsil 19    
Moore et al, 2009 Base of tongue 26 8,9 31,1 17,8
[41] Total 45
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Table 1. Continued.
 Supraglottic 10    
Lawson et al, 2011 Pharynx 10 0 0 nd
[19] Oral cavity 4
Total 24
 Aryepiglottic fold 3    
Piriform sinus 2
Pharynx 5
Aubry et al, 2011 Base of tongue 3 nd 11,8 11,8
[53] Vallecula 1
Epiglottis 2
Arytenoid 2
Total 17
Weinstein et al, 2010 [43] Oropharynx 47 12,8 10,6 2,4
 Supraglottic 2 2    
Benazzo et al, 2012 Oropharynx 4 16,7 100 0
[54] Total 6
Iseli et al 2009 Oropharynx 33
[40] Larynx 12 31,5 9,3 16,7
Oral cavity 6
Hypopharynx 3
Total 54
Sinclair et al, 2011 Tonsil 29
[55] Base of tongue 13 0 0 10
Total 42
Genden et al [16] reported the ability to tolerate an oral diet at a mean of 1.4 days after surgery without any patients requiring gastrostomy 
tubes. Iseli et al reported that 83% patients were tolerating an oral diet within 14 days, while 17% required a feeding tube at 12-month 
follow-up, and 5.6% demonstrated signs or symptoms of aspiration [37]. Moore et al reported that 82% of the patients were tolerating oral 
diet by the first postoperative visit, whereas 17% required a feeding tube, and none required assistance with feeding at one-year follow-up 
[38]. Hurtuk et al reported that 100% of the patients were able to return to oral diet on the day of surgery and 20% of them required feeding 
tubes mainly for adjuvant therapy [39].
The majority of the authors reported a low rate of tracheotomy for patients undergoing TORS (see Table 1 for details). Moreover, most of 
those patients were decannulated within two weeks and no patients required tracheotomy tube at one year after surgery [13].
Oncological outcomes of TORS
The oncological outcomes from TORS are slowly emerging in the literature and they seem promising [13] (Table 2). In the cohort study, on 
47 patients with advanced oropharyngeal carcinoma treated with TORS, Weinstein et al reported a local recurrence rate of 2%, a regional 
recurrence rate of 4%, and a distance recurrence rate of 9% at a minimum of 18 months of follow-up. Overall survival rates were 96% at 
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one year and 82% at two years, with a disease-specific survival of 98% at one year and 90% at two years. The disease-free survival was 
96% at one year and 79% at two years. Extracapsular extension in the metastatic nodal disease was found to be statistically affecting the 
overall survival rates, 38% of the patients avoided chemotherapy and, because of the high rate of negative margins, 11% did not receive 
adjuvant chemoradiotherapy [40].
Table 2. Oncological outcomes of TORS.
Author Primary site Number of  
patients
Follow up 
(months)
Overall
survival (%)
Free of  
disease (%)
 Palatine tonsil 27   
Base of tongue 11
Hurtuk et al, 2011 Larynx 4 16,3 ± 7,5 100 97
[42] Retromolar trigone 1
Parapharynx 1
Total 44
 Tonsil 7    
Base of tongue 3
Genden et al, 2009 Parapharynx 2 5,1 100 100
[16] Hypopharynx 4
Palate 2
Total 18
Oropharynx 18    
Hans et al, 2011 Larynx 5 20,6 100 100
[49] Hypopharynx 2
Total 25
 Oropharynx 44    
Vergez et al, 2012 Hypopharynx 64 nd 98,4 nd
[50] Larynx 18
Total 126
 Pharynx 2    
Remacle et al, 2012 Supraglottic 2 9 100 100
[51] Total 4
 Tonsil 19    
Moore et al, 2009 Base of tongue 26 1–16 97,8 91,1
[41] Total 45
 Supraglottic 10    
Lawson et al, 2011 Pharynx 10 17 nd 91,7
[19] Oral cavity 4
Total 24
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Table 2. Continued.
 Aryepiglottic fold 3    
Piriform sinus 2
Pharynx 5
Aubry et al, 2011 Base of tongue 3 6,5 100 100
[53] Vallecula 1
Epiglottis 2
Arytenoid 2
Total 17
Weinstein et al, 2010 [43] Oropharynx 47 18–44 82 79
 Supraglottic 2 2    
Benazzo et al, 2012 Oropharynx 4 5,8 100 100
[54] Total 6
Oral cavity 2
White et al, 2010 Oropharynx 77 26 100 86.5
[45] Larynx 10
Total 89
Cohen et al reported the outcome profile of oropharyngeal SCC treated with TORS comparing two different groups of patients: HPV-positive 
and negative. In the HPV-positive group (37 patients), the authors reported no local or regional recurrence, though two patients had distant 
recurrences. In the HPV-negative group, there were no local recurrence, one patient had both regional and distant recurrences. Survival 
rates showed no statistically significant differences between the two groups of patients, with 81% in HPV-positive group and 80% in the 
HPV-negative group [41].
White et al in a prospective case study of 89 patients with head and neck SCC of all stages and subsites treated with TORS, reported at a 
median follow-up period of 26 months three patients with local recurrence, seven with regional recurrence (two of whom also had distant 
metastases), and one patient with distant recurrence; seven patients were treated with TORS for recurrent disease. Of the patients who 
underwent TORS as primary treatment, 63% underwent adjuvant radiotherapy and 48% had chemotherapy either before or after surgery; 8% 
underwent salvage TORS after primary chemoradiotherapy. At the last follow-up visit, 82 patients had no evidence of disease, one died of the 
disease, two died of other diseases, and four were alive with disease. The overall two-year recurrence free survival rate was 86.3% [42].
Genden et al in a prospective case-control study of 30 patients with head and neck SCC of all stages and subsites treated with TORS and 
adjuvant therapy, reported 24 patients alive with no recurrent disease at last follow-up visit. Two patients had local recurrence, two devel-
oped distant recurrence, and one developed a second primary tumour. The 18-month locoregional control, distant control, disease-free 
survival, and overall survival reported rates of 91%, 93%, 78%, and 90%, respectively [17].
QOL after TORS
Even if the most important outcome for cancer patients is overall survival, in patients with head and neck cancer, QOL, and functional 
outcome may really be affected by psychological impact of loss of function and physical disfigurement. This has led to a shift to not only 
organ-preservation treatments, but also function-preservation treatments. Frequent problems include difficulty with speech, respiration, and 
eating [13]. Leonhardt et al reported a return to normal swallowing function and diet one year after surgery in 38 patients with oropharyngeal 
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SCC treated with TORS, while the speech domain was significantly reduced even one year after surgery. They reported that patients who 
had TORS followed by chemoradiation had significantly lower swallowing scores compared with those without [43]. 
The case control study on 30 patients with head and neck SCC reported by Genden et al found that patients treated with TORS had 
significantly better short-term swallowing and eating ability and diet compared with patients treated with primary chemoradiation. While 
TORS patients had a return to baseline in all domains (swallowing, eating, and diet) at 12 months, patients who had chemoradiotherapy 
did not have a return to baseline in the diet domain [17].
In a cohort of 64 patients who underwent TORS for benign and malignant lesions of the head and neck region, Hurtuk et al observed the 
resumption of normal oral intake in all but one patient, with no patients who needed tracheostomy. Although in all of the patients, the self-
administered QOL questionnaire underlined a postoperative decreasing in all of the values, at the one-year follow-up the major part of them 
returned back to high domains, with the exception of eating function and attitude. QOL scores differed significantly among patients who 
underwent TORS for malignant diseases compared with those who had a robotic resection for benign lesions; similarly, QOL scores were 
significantly lower for those patients who underwent adjuvant radio- or chemotherapy and in those affected by tonsillar region cancer [18].
The overall hospital stay is reported to be shorter for TORS patients than for those who would have otherwise undergone an open approach. 
In the case series of Moore et al, all the 35 patients were discharged from the hospital within six days [38]; in the study of Boudreaux et al, the 
mean hospital stay reported was 2.6 days [44], whereas in the experience of Weinstein et al, it was between five and seven days [15, 45].
Conclusions
Development of TORS has greatly facilitated the minimally invasive surgical approach for head and neck carcinoma, circumventing 
many of the technical limitations commonly associated with transoral laser microsurgical techniques, such as line of sight and two-
handed surgery. 
TORS provides superb three-dimensional visualisation and magnification in all directions, with tremor filtration, greater freedom of instru-
ment movement facilitating delicate dissection, minimally invasive and less morbid access, and the ability of two surgeons to operate 
within the field. The excellent ability of bleeding control facilitates en bloc complete tumour resection. Technical feasibility, efficacy, and 
safety have been largely demonstrated by many studies. In patients undergoing TORS, shorter operative time and decreased hospital stay 
have been observed; excellent oncological and functional outcomes have been also reported [43]. Faster return to normal function allows 
patients to begin adjuvant therapy, if warranted, much sooner than in patients who undergo open surgery [39], affording potential advan-
tages, and benefits over current treatment modalities of head and neck tumours. 
Not all the patients are good candidates for TORS because some of them may present some limiting factors, mostly affecting proper 
surgical exposure, such as trismus, narrow arched mandible, full dentition, and retrognathia [42]. Access to the tumour may also be 
influenced by the site and the extension of the tumour, and the equipment employable by the surgeon [16]. 
The bigger limitation of robotic technology seems to be represented by the absence of sensory tactile feedback, which may give significant 
drawback in a number of situations [12]. The initial cost of approximately US$1.5 million (coupled with an approximately US$100,000 yearly 
maintenance fee and US$200/case/disposable instrument) is a significant financial investment and it may clearly hinder widespread use. 
However, the benefits of decreased operative time and decreased length of hospital stay could offset this cost [45]. Operating room setup 
time and surgical time can be significantly long at the beginning, but all published articles demonstrated a precipitously and significant 
reduction of those times as the surgeons gained experience with the Da Vinci Surgical System [42] (Table 3).
In terms of the teachability of TORS, training programs have already yielded successes [45]. As for as oncological results, the evaluations 
of the surgical margins seem to confirm that the Da Vinci Surgical System may provide, with an accurate patient selection, complete tumour 
resection with preservation of swallowing function in the majority of cases.
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Table 3. TORS operating room setup and surgical times.
Author Primary site Number of  
patients
Set-up time (min) 
Range (average)
Operative time (min) 
Range (average)
 Tonsil 7   
Base of tongue 3
Genden et al, 2009 Parapharynx 2 20–140 (54,6) 45–150 (84,0)
[16] Hypopharynx 4
Palate 2
Total 18
Oropharynx 18   
Hans et al, 2011 Larynx 5 15–100 (25,0) 20–150 (70,0)
[49] Hypopharynx 2
Total 25
 Oropharynx 44   
Vergez et al, 2012 Hypopharynx 64 52 ± 46 90 ± 92
[50] Larynx 18
Total 126
 Pharynx 2   
Remacle et al, 2012 Supraglottic 2 10–60 (30,0) 60–125 (94,0)
[51] Total 4
Weinstein et al, 2007 [7] Oropharynx 27 2–22 (9,0) 26–233 (84,0)
Park et al, 2009 [52] Tonsil 5 15–25 (19,0) 40–50 (44,0)
 Tonsil 19 54–59 (68,6) first 10 45–320 (71,8) first 10
Moore et al, 2009 [41] Base of tongue 26 14–28 (22,3) other 35 6–309 (71,3) other 35
Total 45 14–59 (32,6) total 6–320 (71,4) total
 Supraglottic 10   
Lawson et al, 2011 [19] Pharynx 10 10–60 (24,0) 12–180 (67,0)
Oral cavity 4
Total 24
 Aryepiglottic fold 3   
Piriform sinus 2
Pharynx 5
Aubry et al, 2011 Base of tongue 3 10–50 (20,5) 10–90 (39,7)
[53] Vallecula 1
Epiglottis 2
Arytenoid 2
Total 17
 Supraglottic 2 2   
Benazzo et al, 2012 Oropharynx 4 nd 35–135 (70,8)
[54] Total 6
Re
vi
ew
 12 www.ecancer.org
ecancer 2013, 7:359
In conclusion, TORS has proven to be a safe and feasible treatment for tumours of the upper aerodigestive tract, and its continuing use 
and development is encouraged; the results of the published articles are still not sufficient to validate the oncological safety of TORS and 
further long-term prospective trials are still needed to confirm those results. 
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